ProPhase Labs, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ted William Karkus
- Full Time Employees
- 19
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 626 RXR Plaz Uniondale NY United States of America 11556
- IPO Date
- Apr 4, 1994
- CIK
- 0000868278
- Website
- prophaselabs.com
- Similar Companies
- Business
- ProPhase Labs, Inc. ProPhase Labs, Inc. (Nasdaq: PRPH) operates as a next-generation biotechnology, genomics, and consumer products company focused on developing, manufacturing, and commercializing innovative health and wellness solutions, including whole genome sequencing services through subsidiaries like Nebula Genomics and DNA Complete; diagnostic testing such as the BE-Smart test for early detection of esophageal cancer; over-the-counter dietary supplements under the TK Supplements brand, featuring Legendz XL, Triple Edge XL, and the immune-boosting Equivir; and contract manufacturing capabilities via Pharmaloz Manufacturing, which produces lozenges and other products. The company serves customers in the United States, including health plans, third-party payers, government organizations, healthcare providers, and direct-to-consumer markets, with primary operations in diagnostics, genomics, and consumer healthcare segments. Founded in 1989 and headquartered in Garden City, New York, ProPhase Labs, Inc. previously operated as The Quigley Corporation and has expanded through key acquisitions, including Nebula Genomics in 2021. Recent developments include securing global private equity backing in late 2024 to support expansion, particularly for distributing TK Supplements in Asia and financing Pharmaloz capacity upgrades; nearing a major lozenge contract projected to add up to $35 million in annual revenue, boosting Pharmaloz run-rate toward $50 million by late 2025; implementing $6 million in annual cost reductions targeting non-core operations; advancing commercialization of the BE-Smart esophageal cancer test following Mayo Clinic validation, with a phased rollout planned for 2026 targeting a $7-14 billion U.S. market; pursuing over $50 million in recoveries from Crown Medical COVID-19 testing receivables via collections, settlements, and Chapter 11 filings by lab subsidiaries; engaging RedChip Companies for investor relations in October 2025; and exploring a cryptocurrency treasury strategy after shareholder approval, while canceling an equity line of credit to avoid dilution.
Company News
Critical Contrast: ProPhase Labs (NASDAQ:PRPH) & Takeda Pharmaceutical (NYSE:TAK)
ProPhase Labs (NASDAQ:PRPH) Shares Pass Below 200 Day Moving Average – What’s Next?
ProPhase Labs (NASDAQ:PRPH) Stock Crosses Below 200 Day Moving Average – What’s Next?
ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform
ProPhase Labs (NASDAQ:PRPH) Shares Pass Below 200 Day Moving Average – Time to Sell?
ProPhase Labs Provides Business Update Highlighting Advancing Crown Medical Collections Activity
ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart™ and Advances Crown Medical Collections Initiative
ProPhase Labs Provides Crown Medical Collections Update; 250+ Insurance Payors Engaged, Approximately 50 Matters in Advanced Settlement Posture
ProPhase Labs (NASDAQ:PRPH) Stock Price Crosses Below Two Hundred Day Moving Average – Should You Sell?
ProPhase Labs (NASDAQ:PRPH) Shares Pass Below Two Hundred Day Moving Average – Time to Sell?
ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value
Head to Head Contrast: Hikma Pharmaceuticals (OTCMKTS:HKMPF) vs. ProPhase Labs (NASDAQ:PRPH)
From Super Fibers to Super Deals: Science, Scale, and Strategic Capital Shape the Morning Tape
ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories
ProPhase Labs (NASDAQ:PRPH) versus Grifols (NASDAQ:GRFS) Head to Head Survey
ProPhase Labs, Inc. (PRPH) Discusses Milestones in Cancer Diagnostics, Genomics Expansion, and COVID Accounts Receivable Collection Transcript
Join ProPhase Labs' Exclusive Live Investor Webinar and Q&A Session on December 1
ProPhase Labs, Inc. (PRPH) Q3 2025 Earnings Call Transcript
ProPhase Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET.
ProPhase Labs, Inc. to Present Third Quarter 2025 Financial Results on November 19